Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02608268 · ClinicalTrials.gov registry record · Phase 1
Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 252
- Enrollment target
NCT02608268 is a Phase 1 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 252 participants.
The verdict
NCT02608268, a Phase 1 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 252 participants
- Enrollment target
Study Summary
The purpose of this first-in-human study of MBG453 was to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of MBG453 administered i.v. as a single agent or in combination with PDR001 or decitabine in adult patients with advanced solid tumors
Interventions
- DRUG Decitabine
- DRUG PDR001
- DRUG MBG453
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 252 participants |
| Start Date | 2015-11-23 |
| Est. Completion | 2022-08-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02608268
The ClinicalTrials.gov registry entry for NCT02608268 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 252 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Decitabine is the first listed.
NCT02608268 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02608268 about?
NCT02608268 is a clinical study titled "Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies". The purpose of this first-in-human study of MBG453 was to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of MBG453 administered i.v. as a single agent or in combination with PDR001 or decitabine in adult patients with advanced solid tumors
What is the current status of trial NCT02608268?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 252 participants. The study started on 2015-11-23. Estimated completion is 2022-08-30.
What interventions are being tested in trial NCT02608268?
The interventions under investigation include: Decitabine (DRUG), PDR001 (DRUG), MBG453 (DRUG).
Who is sponsoring clinical trial NCT02608268?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.